TSVT vs. TKNO, SNDL, TRDA, KMDA, MLYS, RNAC, ALT, MREO, PROK, and ERAS
Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Alpha Teknova (TKNO), SNDL (SNDL), Entrada Therapeutics (TRDA), Kamada (KMDA), Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Altimmune (ALT), Mereo BioPharma Group (MREO), ProKidney (PROK), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.
2seventy bio vs.
2seventy bio (NASDAQ:TSVT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
In the previous week, 2seventy bio had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 4 mentions for 2seventy bio and 3 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 0.95 beat 2seventy bio's score of 0.32 indicating that Alpha Teknova is being referred to more favorably in the news media.
Alpha Teknova has lower revenue, but higher earnings than 2seventy bio. Alpha Teknova is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks.
2seventy bio presently has a consensus target price of $7.20, indicating a potential upside of 171.70%. Alpha Teknova has a consensus target price of $8.50, indicating a potential upside of 12.60%. Given 2seventy bio's higher possible upside, research analysts clearly believe 2seventy bio is more favorable than Alpha Teknova.
Alpha Teknova has a net margin of -87.17% compared to 2seventy bio's net margin of -207.25%. Alpha Teknova's return on equity of -35.30% beat 2seventy bio's return on equity.
93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
2seventy bio has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.
2seventy bio received 16 more outperform votes than Alpha Teknova when rated by MarketBeat users. Likewise, 52.08% of users gave 2seventy bio an outperform vote while only 39.13% of users gave Alpha Teknova an outperform vote.
Summary
2seventy bio beats Alpha Teknova on 10 of the 18 factors compared between the two stocks.
Get 2seventy bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
2seventy bio Competitors List
Related Companies and Tools
This page (NASDAQ:TSVT) was last updated on 2/21/2025 by MarketBeat.com Staff
